Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II

This research study will test an investigational medication called KVD900, a new oral drug being developed to treat hereditary angioedema, the same condition you have. This study is being done to understand how well one or two doses of KVD900 300mg or KVD900 600mg works against placebo to bring relief from an attack of HAE.
Kristina Richwine at krichwine@pennstatehealth.psu.edu or 717-531-4506
All
All
This study is NOT accepting healthy volunteers
NCT05259917
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male or female patients 12 years of age and older.
Confirmed diagnosis of HAE type I or II at any time in the medical history.
Patient has access to and ability to use conventional on-demand treatment for HAE attacks.
Patient provides signed informed consent or assent (when applicable). A parent or legally authorized representative must also provide signed informed consent when required.
Patients must be able to swallow trial tablets whole.
Exclusion Criteria:
Any pregnant or breastfeeding patient.
Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit.
History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA